Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review.

Respir Res · 2025 · PMC12574037 · PMID 41163220

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The COPD-ST2OP trial ( NCT03615040 ; 4 May 2018) in 81 patients with moderate-to-very-severe COPD, showed a clinically meaningful reduction in the annual exacerbation rate of 22% for astegolimab versus placebo, though this result did not reach statistical significance [ 19 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.